<?php include_once "../../_head.php";?>
	<div id="visaul" class=" s4"></div>
	<div id="content">
		<div class="conts">
			<section>
				<div class="in_conts">
					<table class="board_list view">
						<caption>view페이지</caption>
						<colgroup>
							<col style="width:130px;" />
							<col style="*" />
						</colgroup>
						<thead>
							<tr>
								<th colspan="2">
									<h3>National OncoVenture (NOV) announces the support of development of MedPacto’s leading anticancer drug candidate, TEW-7197</h3>
									<div><span>Mar 14, 2018</span><span>Search Engine Watch</span><span>Hit 6371</span></div>
								</th>
							</tr>
						</thead>
						<tbody>
							<tr>
								<td class="txt" colspan="2">
									As part of the 10-year plan to conquer national cancer, the National Cancer Center's Agency (Kim In-cheol) selected two samples<br />
									of the anti-carcinogy drugs tested by Korean biochemist and pharmaceutical companies.<br />
									<br />
									The project group decided to conduct the initial clinical trial of indications on metamorphic solid cancers with TEW-71997, <br />
									the biochemistry compound selected in the first public offering.<br />
									<br />
									The target material is a project to find new substances and transfer them to domestic and overseas companies by using the support<br />
									of Professor Kim Dae-ki of Ewha Womans University.<br />
									<br />
									The business group also signed a contract to develop oral cancer drugs with Jonggeundang (Jonggeundang),<br />
									the owner of the materials company, on " eun .-16, " selected in the third public offering.<br />
									<br />
									The substance is currently in its first phase of clinical trial with a syringe at each event, and the project team aims to develop oral drugs.<br />
									<br />
									The project group expects that if the possibility of oral administration is confirmed through clinical testing, it will receive attention<br />
									as a new anti-cancer drugs in the global market.<br />
									<br />
									A source at the project group said, " Since its launch in 2011, the business group has co-collected a total of seven occasions<br />
									with materials for providing new drugs for development.<br />
								</td>
							</tr>
							<tr>
								<td colspan="2">
									<strong>The attached file</strong>
									<a href="">MedPacto’s leading anticancer drug candidate.pdf</a>
								</td>
							</tr>
							<tr>
								<th class="txt_prev">Previous</th>
								<td><a href="javascript:void(0);">MedPacto gets an approval of IND for TEW-7197 from US FDA.</a></td>
							</tr>
							<tr>
								<th class="txt_next">Next</th>
								<td><a href="javascript:void(0);">Medpacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.</a></td>
							</tr>
						</tbody>
					</table>
					<div class="w_bt_center">
						<a href="javascript:void(0);" class="bt_2s">Delete</a>
						<a href="javascript:void(0);" class="bt_1s">Modify</a>
						<a href="/page/s4/s1.php" class="bt_1s">List</a>
					</div>
				</div>
			</section>
		</div>
	</div>
<?php include_once "../../_tail.php";?>